ACAD - ACADIA PHARMACEUTICALS INC

QQQ $ 633.20 nm (nm)

DIA $ 475.83 $ -1.36 (-0.29 %)

SPY $ 684.43 nm (nm)

TLT $ 90.42 nm (nm)

GLD $ 371.67 $ 7.13 (1.96 %)

Previous Close

$ 22.74

Open

$ 22.24

Bid

$ 22.00 x 100

Ask

$ 22.70 x 37

Day's Range

$ 22.15 - $ 22.88

52 Week Range

$ 13.40 - $ 26.65

Volume

1,190,343

Average Volume

Market Cap

3.84B

Beta (5Y Monthly)

$ 0.69

PE Ratio (TTM)

$ 17.27

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2025	06-30-2025	10-Q
2	05-08-2025	03-31-2025	10-Q
3	02-27-2025	12-31-2024	10-K
4	11-06-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	02-28-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-02-2023	06-30-2023	10-Q
10	05-08-2023	03-31-2023	10-Q
11	02-28-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-08-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	03-01-2022	12-31-2021	10-K
16	11-08-2021	09-30-2021	10-Q
17	08-04-2021	06-30-2021	10-Q
18	05-06-2021	03-31-2021	10-Q
19	02-25-2021	12-31-2020	10-K
20	11-04-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-08-2020	03-31-2020	10-Q
23	02-27-2020	12-31-2019	10-K
24	10-31-2019	09-30-2019	10-Q
25	08-01-2019	06-30-2019	10-Q
26	05-02-2019	03-31-2019	10-Q
27	02-27-2019	12-31-2018	10-K
28	11-06-2018	09-30-2018	10-Q
29	08-08-2018	06-30-2018	10-Q
30	05-04-2018	03-31-2018	10-Q
31	02-27-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-08-2017	06-30-2017	10-Q
34	05-09-2017	03-31-2017	10-Q
35	02-28-2017	12-31-2016	10-K
36	11-07-2016	09-30-2016	10-Q
37	08-04-2016	06-30-2016	10-Q
38	05-05-2016	03-31-2016	10-Q
39	02-29-2016	12-31-2015	10-K
40	11-05-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

this-acadia-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday

This ACADIA Pharmaceuticals Analyst Begins...
10/21/2025 12:35:30

Citigroup Initiates Coverage On ACADIA Pha...
10/21/2025 10:51:16

Citigroup analyst Yigal Nochomovitz initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy rating and announc...

Acadia Pharmaceuticals To Present ACP-711 ...
10/02/2025 13:06:46

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced one late-breaker oral platform presentation and two poster presentati...

Beyond The Numbers: 11 Analysts Discuss AC...
09/29/2025 14:03:05

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide a...

JP Morgan Maintains Overweight on ACADIA P...
09/29/2025 12:10:00

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Overweight and lowers the price target...

Needham Maintains Buy on ACADIA Pharmaceut...
09/24/2025 14:54:06

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...

acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short

Acadia Pharma Faces Trial Setback As Prade...
09/24/2025 14:05:05

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...

12 Health Care Stocks Moving In Wednesday'...
09/24/2025 12:10:28

Trading Halt: Halt status updated at 7:25:...
09/24/2025 11:25:04

Acadia's Phase 3 COMPASS PWS Trial Of Intr...
09/24/2025 11:02:53

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ef...

Trading Halt: Halted at 6:55:13 a.m. ET - ...
09/24/2025 10:55:17

Acadia Pharma Announces Publication Of Int...
09/12/2025 20:07:49

-- Findings reinforce efficacy and tolerability profile in patients prescribed DAYBUE in the U.S. for as long as 12 months, con...

TD Cowen Maintains Buy on ACADIA Pharmaceu...
09/11/2025 13:20:06

TD Cowen analyst Ritu Baral maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 t...

Assessing ACADIA Pharmaceuticals: Insights...
09/09/2025 18:01:15

UBS Maintains Buy on ACADIA Pharmaceutical...
09/09/2025 14:47:17

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to ...

UBS Maintains Buy on ACADIA Pharmaceutical...
08/08/2025 15:49:52

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to ...

Goldman Sachs Maintains Sell on ACADIA Pha...
08/07/2025 16:58:49

Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Sell and raises the price target...

RBC Capital Maintains Outperform on ACADIA...
08/07/2025 14:31:00

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price tar...

JMP Securities Maintains Market Outperform...
08/07/2025 13:20:26

JMP Securities analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and raises th...

Mizuho Maintains Neutral on ACADIA Pharmac...
08/07/2025 13:19:18

Mizuho analyst Uy Ear maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $23 to ...